Biotech Roundup: CRISPR’s 1st Trial, IPO Insiders, Zika & More – Xconomy
|
Biotech Roundup: CRISPR's 1st Trial, IPO Insiders, Zika & More
Xconomy Slightly fewer people paid attention to another historic vote: An NIH panel approved plans for what could be the first-ever human clinical trial of CRISPR-Cas9, the gene editing system that has been taking the scientific world by storm over the past … |
